AbbVie Inc. (NYSE:ABBV)

CAPS Rating: 5 out of 5

Results 1 - 20 of 25 : 1 2 Next »

Recs

0
Member Avatar cryptelligence (59.55) Submitted: 7/3/2014 6:48:36 PM : Outperform Start Price: $57.47 ABBV Score: -6.05

Algae Play

Recs

1
Member Avatar BaseBawl (23.40) Submitted: 5/29/2014 9:44:04 AM : Outperform Start Price: $53.89 ABBV Score: -2.98

4 more dogs of the dividend aristocrats that I didn't already have. Hudspeth.

Recs

0
Member Avatar ZipMeck (47.88) Submitted: 3/2/2014 11:51:23 AM : Outperform Start Price: $49.51 ABBV Score: +1.90

Have a few in the pipeline coming up in phase 111 and also reviews coming up.

Recs

0
Member Avatar TerryFool (< 20) Submitted: 2/6/2014 9:36:31 AM : Outperform Start Price: $49.86 ABBV Score: +1.22

invest, ABBV BP 47.0 TP 54.3 2.2 5star

Recs

0
Member Avatar rjs157 (61.95) Submitted: 1/21/2014 4:39:22 PM : Outperform Start Price: $49.16 ABBV Score: +2.57

ABT spin off, will do well

Recs

0
Member Avatar drugstock2 (< 20) Submitted: 1/19/2014 3:43:50 PM : Outperform Start Price: $49.23 ABBV Score: +2.54

Humira will provide ABBV with a steady stream of cash to support a healthy dividend, and fund new product development and acquisitions.

Recs

0
Member Avatar grankh (70.68) Submitted: 12/13/2013 1:04:45 PM : Outperform Start Price: $50.21 ABBV Score: -1.50

I own this stock through my Investment Club, which bought it this month.

Since it was only spun off from Abbott Labs earlier this year, I don't have as much data on this stock as I would normally like before purchasing it. But the club liked it, so we bought it.

Sales have increased at an annual compound rate of over 5% since 2011. EPS increased at a compound rate of over 12% from 2010 to 2012. The profit margin has been fluctuating a lot, but was 31% last year, which is pretty good. The return-on-equity was 47%, which is pretty good. However, the debt-to-equity was 423%, which is pretty high in my book, so Abbott Labs loaded up their spin off with debt before spinning it off. Not amongst my favorite things. The current P/E is more than double its highest P/E from last year, so the stock seems expensive on that metric. The PEG ratio comes in at 2.35, which is very expensive. The company pays about a 3% dividend, which is pretty good.

I show this stock as a Hold, with an expected annual return of about 8%. The person who presented the stock thinks we will get significantly more than that. We'll have to wait and see which of us is correct.

Recs

0
Member Avatar line70day (< 20) Submitted: 11/6/2013 3:48:20 PM : Outperform Start Price: $51.40 ABBV Score: -4.37

Jan 1 20113 ABBV became independent
Cash flow & equivalent at end of period
$8,743 2013 $74 2012
rev growth 1 yr 5.40% eps 53.70%
rev trailing 12Q 9.02 B
ers 1.27ytd
div ytd 0.80

Recs

0
Member Avatar mike042180 (< 20) Submitted: 10/26/2013 10:47:41 AM : Outperform Start Price: $47.95 ABBV Score: +0.12

outperform

Recs

1
Member Avatar SnowBawl (< 20) Submitted: 8/22/2013 7:55:46 AM : Outperform Start Price: $41.01 ABBV Score: +11.60

TSA Abbott spinoff. Growth and yield.

Recs

1
Member Avatar TMFEBCapital (< 20) Submitted: 8/13/2013 10:19:04 AM : Outperform Start Price: $43.53 ABBV Score: +6.63

AbbVie has a chance to beat Gilead in the race to gain approval for the first all oral Hep C treatment for the most common genotype 1.

Recs

0
Member Avatar ptanabe (60.30) Submitted: 8/1/2013 3:59:16 PM : Outperform Start Price: $43.61 ABBV Score: +6.77

tw

Recs

0
Member Avatar TerryHoodSr (48.28) Submitted: 7/29/2013 10:57:07 PM : Outperform Start Price: $45.57 ABBV Score: +9.83

steady

Recs

0
Member Avatar reynman1 (< 20) Submitted: 6/13/2013 10:34:51 PM : Outperform Start Price: $41.20 ABBV Score: +10.37

Hep C cure and new drug pipeline

Recs

1
Member Avatar cschweit (37.87) Submitted: 5/23/2013 4:39:17 PM : Outperform Start Price: $44.33 ABBV Score: +1.47

This stock will be quite volitile for the next few years, but it's pipeline is strong. If the pipeline is delivered, this will be a strong company for years to come. 2016 is the "big" year according to many analysts because of Humira patent protection loss, but this is an overhyped notion based on trends in the pharmaceutical market in general, not specifically based on the type of product it is. Since Humira is a biologic, creating a generic (bio-similar) is much more difficult to do, and much more difficult to get approved. The "patent cliff" is typically more important when it comes to small molecule drugs because generics are much easier to develop for these types of medicines. While the patent is worrysome, it's not to the extent that many analysts believe. The next few years will be crucial, though, for this young company - especially with the race with Gillead over Hepatitus C medicines.

Recs

0
Member Avatar j8h9 (< 20) Submitted: 5/8/2013 6:01:37 PM : Outperform Start Price: $41.55 ABBV Score: +8.73

Fantastic dividend and growth here. This is Abbotts business

Recs

0
Member Avatar kainvest (48.30) Submitted: 4/16/2013 11:43:02 AM : Outperform Start Price: $39.91 ABBV Score: +9.07

Could be in sweet spot for market performance

Recs

1
Member Avatar IfHeDiesHeDies (73.96) Submitted: 4/8/2013 7:21:52 PM : Outperform Start Price: $39.86 ABBV Score: +9.00

A+

Recs

1
Member Avatar DirkaDirka (74.85) Submitted: 3/15/2013 6:18:57 PM : Outperform Start Price: $35.12 ABBV Score: +20.23

Some P/E ratios for comparison:
BMY 33.79
MRK 21.99
PFE 22.24
JNJ 20.50

And...
ABBV 12.44

P/E isn't everything, but ROE and ROA are pretty outstanding as well in comparison. Yes there are worries about being reliant on one drug, but there's plenty of time to bail if nothing promising comes down the pipeline. In the meantime, revenues from Humira are increasing, which means good things for about 2 more years at least. This is a classic undervalued spinoff, despite the large size.

Recs

0
Member Avatar ausgmblr (< 20) Submitted: 2/5/2013 7:17:24 PM : Outperform Start Price: $35.31 ABBV Score: +21.46

MEDICAL SEC. result of 2/1 split from ABT last month should be good appreciation.

Results 1 - 20 of 25 : 1 2 Next »

Featured Broker Partners


Advertisement